Cadila Healthcare rose 1.85% to Rs 407.95 at 13:23 IST on BSE after the company received the tentative approval from the USFDA to market Tadalafil tablets.
The announcement was made during market hours today, 19 June 2018.Meanwhile, the S&P BSE Sensex was down 214.23 points, or 0.6% to 35,334.03.
On the BSE, 1.13 lakh shares were traded in the counter so far compared with average daily volumes of 1.68 lakh shares in the past two weeks. The stock had hit a high of Rs 409.70 and a low of Rs 399.05 so far during the day. The stock hit a record high of Rs 554.20 on 25 July 2017. The stock hit a 52-week low of Rs 341.65 on 22 May 2018.
The large-cap company has equity capital of Rs 102.37 crore. Face value per share is Re 1.
Zydus Cadila has received the tentative approval from the USFDA to market Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg and 20 mg. It is used to treat erectile dysfunction (impotence) and symptoms of benign prostatic hypertrophy (enlarged prostate). It will be manufactured at the group's manufacturing facility at Moraiya, Ahmedabad.
The group now has more than 195 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
On a consolidated basis, net profit of Cadila Healthcare rose 53.26% to Rs 590.80 crore on 31.03% rise in net sales to Rs 3152.70 crore in Q4 March 2018 over Q4 March 2017.
Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
